>> alnylam could be a wordle world. of moves going after companies called attr cardiomyopathy. releasing the results of its drug and looked like the company had a lock on this market when they shared high-level data this summer. remember that data's stock went up 30%, but today's closer look suggesting it might not be the grand slam that alnylam made it seem. bridgebio's drug under fda review and that decision is expected in november. now alnylam is still confident in these results and they plan to file regulatory applications by the end of this year. these questions are weighing on some of the other names taking similar approaches. look at intelli and ionis. >> so plane in the biotech space. we'll leave it to you. i couldn't tell you what 90% of them do. that's why we have angelica. it says here, santoli's last word. not ever, just today. >> not ever not wordle words because i don't play the game -- >> what's wrong with you? >> i don't like games. >> talk about the stock market. >> exactly. >> this is the biggest game.